Name | Number of supported studies | Average coverage | |
---|---|---|---|
plasma cell | 9 studies | 22% ± 9% | |
B cell | 7 studies | 21% ± 5% | |
precursor B cell | 5 studies | 37% ± 12% | |
endothelial cell | 5 studies | 23% ± 6% | |
regulatory T cell | 5 studies | 19% ± 4% | |
naive B cell | 4 studies | 19% ± 2% | |
endothelial cell of vascular tree | 4 studies | 20% ± 7% | |
plasmablast | 3 studies | 38% ± 14% | |
pro-B cell | 3 studies | 28% ± 2% |
Insufficient scRNA-seq data for expression of TIFA at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
thymus | 100% | 999.38 | 653 / 653 | 99% | 15.58 | 601 / 605 |
ovary | 100% | 694.87 | 180 / 180 | 99% | 10.55 | 425 / 430 |
breast | 99% | 668.59 | 455 / 459 | 99% | 19.55 | 1111 / 1118 |
lung | 99% | 662.59 | 573 / 578 | 99% | 12.12 | 1141 / 1155 |
bladder | 100% | 564.52 | 21 / 21 | 98% | 12.12 | 493 / 504 |
pancreas | 100% | 1665.47 | 328 / 328 | 98% | 8.18 | 174 / 178 |
prostate | 99% | 556.85 | 242 / 245 | 99% | 13.85 | 495 / 502 |
uterus | 99% | 412.75 | 168 / 170 | 98% | 15.35 | 452 / 459 |
esophagus | 100% | 773.18 | 1443 / 1445 | 97% | 9.28 | 178 / 183 |
stomach | 100% | 630.89 | 358 / 359 | 92% | 7.52 | 264 / 286 |
intestine | 98% | 482.14 | 949 / 966 | 94% | 8.68 | 493 / 527 |
kidney | 97% | 329.70 | 86 / 89 | 90% | 8.38 | 808 / 901 |
skin | 100% | 818.08 | 1807 / 1809 | 85% | 6.92 | 400 / 472 |
liver | 100% | 526.37 | 225 / 226 | 78% | 6.11 | 317 / 406 |
adrenal gland | 95% | 535.21 | 244 / 258 | 57% | 3.24 | 132 / 230 |
brain | 64% | 213.82 | 1699 / 2642 | 43% | 3.11 | 303 / 705 |
lymph node | 0% | 0 | 0 / 0 | 100% | 34.35 | 29 / 29 |
spleen | 100% | 1120.97 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 20.06 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 3.23 | 1 / 1 |
adipose | 99% | 515.03 | 1197 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 99% | 626.01 | 1326 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 96% | 2271.71 | 896 / 929 | 0% | 0 | 0 / 0 |
heart | 93% | 450.84 | 802 / 861 | 0% | 0 | 0 / 0 |
muscle | 57% | 117.11 | 457 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 24% | 1.11 | 19 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0051260 | Biological process | protein homooligomerization |
GO_0043123 | Biological process | positive regulation of canonical NF-kappaB signal transduction |
GO_0002753 | Biological process | cytoplasmic pattern recognition receptor signaling pathway |
GO_0033209 | Biological process | tumor necrosis factor-mediated signaling pathway |
GO_0045087 | Biological process | innate immune response |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0005515 | Molecular function | protein binding |
Gene name | TIFA |
Protein name | TRAF-interacting protein with FHA domain-containing protein A (Putative MAPK-activating protein PM14) (Putative NF-kappa-B-activating protein 20) (TRAF2-binding protein) TIFA protein |
Synonyms | T2BP |
Description | FUNCTION: Adapter molecule that plays a key role in the activation of pro-inflammatory NF-kappa-B signaling following detection of bacterial pathogen-associated molecular pattern metabolites (PAMPs) . Promotes activation of an innate immune response by inducing the oligomerization and polyubiquitination of TRAF6, which leads to the activation of TAK1 and IKK through a proteasome-independent mechanism . TIFA-dependent innate immune response is triggered by ADP-D-glycero-beta-D-manno-heptose (ADP-Heptose), a potent PAMP present in all Gram-negative and some Gram-positive bacteria: ADP-Heptose is recognized by ALPK1, which phosphorylates TIFA at Thr-9, leading to TIFA homooligomerization and subsequent activation of pro-inflammatory NF-kappa-B signaling . . |
Accessions | ENST00000500655.2 ENST00000361717.4 I6L962 Q96CG3 ENST00000610220.2 |